RESUMO
We report the use of injectable poly-l-lactic acid (PLLA) for volume restoration in a 45-year-old white female who was concerned about the appearance of her hands. The patient expressed a desire for long-term restoration, and selected injectable PLLA because of its known 2-year duration of effect, although she was informed that injectable PLLA is not FDA-approved for use in the hands. After reconstitution with 8 ml of diluent plus lidocaine, 0.1-0.2-ml aliquots of injectable PLLA were injected into selected sites, up to 5 ml per hand. The patient underwent three identical treatments, followed by postinjection use of moisturizing cream and massage; improvement in appearance was noted by the patient between the second and third treatments. Correction was maintained for at least 18 months, with no adverse events. We have also briefly reviewed the literature on the use of injectable PLLA for volume restoration in the hand.
Assuntos
Materiais Biocompatíveis/uso terapêutico , Técnicas Cosméticas , Mãos , Ácido Láctico/uso terapêutico , Polímeros/uso terapêutico , Envelhecimento da Pele/efeitos dos fármacos , Feminino , Humanos , Injeções , Pessoa de Meia-Idade , Uso Off-Label , Poliésteres , RejuvenescimentoRESUMO
PURPOSE: To examine the relationship between retinal ganglion cell function measured using pattern electroretinogram optimized for glaucoma screening (PERGLA), retinal nerve fiber layer (RNFL) thickness, and optic nerve head topography. METHODS: Twenty-nine normal, 28 glaucoma, and 37 glaucoma suspect volunteers were enrolled. All participants were age similar. One randomly selected eye underwent complete eye examination, standard automated perimetry (SAP), scanning laser polarimetry with enhanced corneal compensation (GDxECC), optical coherence tomography, Heidelberg retina tomograph (HRT), and PERGLA measurements. PERGLA amplitude (microV) was converted to dB for comparison with SAP mean deviation (MD) and pattern SD. The correlation between PERGLA amplitude in dB and the average of sensitivity values for 16 central test locations of SAP were calculated. Analysis of variance, Pearson and Spearman rank correlations, coefficient of variation, and intraclass correlation coefficients were calculated. RESULTS: PERGLA amplitude in glaucomatous eyes was significantly lower than normal eyes (0.47+/-0.20 vs. 0.70+/-0.28 microV, P<0.001) but not glaucoma suspects (0.54+/-0.21 microV, P=0.84). PERGLA amplitude was inversely correlated with age (r=-0.31, P=0.002). PERGLA amplitude (in dB) was associated with the sensitivity values of the SAP central 16 test locations (r=0.40, P<0001) across the entire cohort, GDxECC superior RNFL thickness (r=0.38, P<0.001), and HRT Moorfields regression analysis classification (rho=-0.34, P=0.001). The coefficient of variation and intraclass correlation coefficients were 14.5% and 0.89 for PERGLA amplitude, 2.4% and 0.98 for optical coherence tomography average RNFL, 2.2% and 0.97 for GDxECC temporal superior nasal inferior temporal average, and 6.3% and 0.94 for HRT rim area. CONCLUSIONS: Retinal ganglion cell function measured using PERGLA is reduced in glaucoma and demonstrates modest correlations with central SAP sensitivity values and structural measures of optic nerve topography and RNFL thickness.